



Company Contact:
Richard Gabriel
CEO and President
941 366-3400

-or-

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

**DNAPRINT'S ELLIPSIS BIOTHERAPEUTICS SUBSIDIARY TO EXHIBIT AT
THE AMERICAN SOCIETY OF HUMAN GENETICS MEETING**

TORONTO & SARASOTA, Fla., Oct. 9, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that representatives of Ellipsis Biotherapeutics Corporation, a wholly owned subsidiary of DNAPrint Genomics, will exhibit at the American Society of Human Genetics Meeting, the premier annual international human genetics meeting, to be held at the Ernest N. Morial Convention Center, starting today and continuing through October 13 in New Orleans.

Ellipsis will introduce several new service offerings in the areas of whole genome association studies and RNA. In addition, the company will exhibit its single nucleotide polymorphism (SNP) genotyping services using both the Illumina GoldenGate™ and Beckman Coulter SNPstream™ technologies, which allow the Company to accommodate all SNP genotyping projects regardless of size. SNPs are DNA sequence variations that can have a major impact on how humans react to diseases and changes in the environment. Ellipsis will exhibit its full array of genetic tests and gene discovery methods.

Based in Toronto, Ellipsis Biotherapeutics Corporation provides commercial genotyping services, including research capabilities for development of novel genetic tests and gene discovery. As part of its founding mission to investigate genetic susceptibility to inflammatory disease, Ellipsis established fully automated high throughput SNP analysis capabilities. Ellipsis has leveraged this core expertise in human disease research and genetic analysis to provide superior quality genotyping services to government, academic and industrial clients. For more information, visit the Ellipsis website at www.ellipsisbio.com.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnprint.com for information on law enforcement and

consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###